Premium
Effective anti‐programmed death‐1 therapy in a SUFU ‐mutated patient with Gorlin–Goltz syndrome
Author(s) -
Moreira A.,
Kirchberger M.C.,
Toussaint F.,
Erdmann M.,
Schuler G.,
Heinzerling L.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16607
Subject(s) - vismodegib , medicine , pembrolizumab , trunk , imiquimod , oncology , surgery , dermatology , basal cell carcinoma , basal cell , immunotherapy , cancer , biology , ecology
Summary We present the case of a 77‐year‐old male patient with more than 50 basal cell carcinomas on the head and upper trunk. The patient did not respond to several lines of treatment, including surgery, imiquimod, retinoids, itraconazole and therapy with the hedgehog inhibitor vismodegib. The patient responded well to off‐label therapy with the anti‐programmed death‐1 antibody pembrolizumab after four infusions.